Omega Fund Management
Omega Fund Management reported 10 stocks worth $186M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are BCAX (29.1%), NUVB (24.7%) and KMTS (14.0%). Compared with Q1 2026, the fund opened new positions in ODTX, trimmed BCAX and sold out of REPL.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  BCAX Bicara Therapeutics Inc | $54.1M | 29.1% | 1.8M | −570K (−24%) | 8 of 8 | |
| 2 |  NUVB Nuvation Bio Inc | $45.9M | 24.7% | 8.1M | No change | 8 of 8 | |
| 3 |  KMTS Kestra Med Technologies Ltd | $26M | 14.0% | 1M | No change | 6 of 8 | |
| 4 |  BBOT Bridgebio Oncology Therapeut | $25.1M | 13.5% | 3.3M | No change | 4 of 8 | |
| 5 |  BBNX Beta Bionics Inc | $20.6M | 11.1% | 1.3M | No change | 6 of 8 | |
| 6 |  ALMS Alumis Inc | $6.8M | 3.7% | 241K | No change | 8 of 8 | |
| 7 |  SANA Sana Biotechnology Inc | $2.9M | 1.6% | 844K | No change | 8 of 8 | |
| 8 |  IMA Imagenebio Inc | $2.7M | 1.4% | 455K | No change | 4 of 8 | |
| 9 | ENGENE HOLDINGS INC | $1.5M | 0.8% | 876K | No change | 8 of 8 | |
| 10 |  ODTX Odyssey Therapeutics, Inc. | $54K | 0.0% | 2,893 | New position | 1 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 REPL Replimune Group Inc | $1.9M | 249K |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Omega Fund Management 13F FAQ
What does Omega Fund Management own?
Omega Fund Management reported 10 stocks worth $186M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are BCAX (29.1%), NUVB (24.7%) and KMTS (14.0%). The table above lists every position in the filing (the top 10 without an account).
What did Omega Fund Management buy and sell in Q2 2026?
Compared with Q1 2026: 1 new positions, 0 added to, 1 trimmed and 1 sold out. New positions include ODTX. It sold all of REPL.
When will Omega Fund Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Omega Fund Management's portfolio worth?
The Q2 2026 filing reports $186M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.